Literature DB >> 19553629

Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases.

Haochuan Li1, Wanhua Yang, Peter W Chen, Hassan Alizadeh, Jerry Y Niederkorn.   

Abstract

PURPOSE: To determine whether blocking the expression of the chemokine receptor CXCR4 using siRNA inhibits chemotactic responses of human uveal melanoma cells to liver-derived factors and prevents liver metastases.
METHODS: Human uveal melanoma cells were transfected with CXCR4 siRNA or control siRNA and tested in vitro for chemotactic and invasive behavior in response to soluble factors produced by human liver cells. The effect of CXCR4 siRNA transfection on the formation of liver metastases was tested by injecting transfected melanoma cells into the spleen capsules of NOD-SCID mice, and metastases were quantified by measuring the human housekeeping gene hHPRT in livers.
RESULTS: Blocking CXCR4 interaction with its ligand using anti-CXCL12 antibody resulted in a significant reduction in the chemotactic responses of uveal melanoma cells to soluble factors produced by human liver cells. Similarly, blocking CXCR4 gene expression by transfection with CXCR4 siRNA inhibited both the chemotactic and the invasive properties of uveal melanoma cells exposed to factors produced by human livers. Uveal melanoma cells transfected with CXCR4 siRNA produced fewer liver metastases than untreated uveal melanoma cells or uveal melanoma cells transfected with control siRNA.
CONCLUSIONS: CXCR4 is a key chemokine receptor that may account for the organ-specific homing of human uveal melanomas to the liver, which contains significant quantities of CXCL2, the only known ligand for CXCR4. CXCR4 is a potential therapeutic target for preventing the initial establishment of liver metastases but has limited application for use in advanced liver tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553629      PMCID: PMC2841954          DOI: 10.1167/iovs.09-3804

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  45 in total

1.  Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.

Authors:  Yu-Ping Jiang; Xiao-Hua Wu; Bin Shi; Wen-Xin Wu; Gui-Ran Yin
Journal:  Gynecol Oncol       Date:  2006-05-02       Impact factor: 5.482

Review 2.  Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.

Authors:  Abid Khan; John Greenman; Stephen J Archibald
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

3.  Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression.

Authors:  T Koshiba; R Hosotani; Y Miyamoto; J Ida; S Tsuji; S Nakajima; M Kawaguchi; H Kobayashi; R Doi; T Hori; N Fujii; M Imamura
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

4.  Involvement of chemokine receptors in breast cancer metastasis.

Authors:  A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

5.  Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.

Authors:  Chih-Hung Lee; Takashi Kakinuma; Julia Wang; Hong Zhang; Douglas C Palmer; Nicholas P Restifo; Sam T Hwang
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

Review 6.  Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response.

Authors:  Keiichi Koizumi; Shozo Hojo; Takuya Akashi; Kazuo Yasumoto; Ikuo Saiki
Journal:  Cancer Sci       Date:  2007-11       Impact factor: 6.716

7.  Differential expression of chemokine receptors on uveal melanoma cells and their metastases.

Authors:  Haochuan Li; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02       Impact factor: 4.799

Review 8.  Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration.

Authors:  Manit Arya; Hashim Ahmed; Nitika Silhi; Magali Williamson; Hiten R H Patel
Journal:  Tumour Biol       Date:  2007-05-18

9.  Cancer stem cells and tumor metastasis: first steps into uncharted territory.

Authors:  Piero Dalerba; Michael F Clarke
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

10.  CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type.

Authors:  Stefania Scala; Caterina Ieranò; Alessandro Ottaiano; Renato Franco; Anna La Mura; Giuseppina Liguori; Massimo Mascolo; Stefania Staibano; Paolo A Ascierto; Gerardo Botti; Gaetano De Rosa; Giuseppe Castello
Journal:  Cancer Immunol Immunother       Date:  2007-04-05       Impact factor: 6.968

View more
  12 in total

1.  Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma.

Authors:  Lei Dong; Shuo You; Qing Zhang; Satoru Osuka; Narra S Devi; Stefan Kaluz; Jalisa H Ferguson; Hua Yang; Guoliang Chen; Binghe Wang; Hans E Grossniklaus; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

2.  Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in a breast cancer cell line.

Authors:  Xiao-Ping Chen; Lin-Lin Qian; Hong Jiang; Jiang-Hua Chen
Journal:  Int J Clin Oncol       Date:  2011-04-01       Impact factor: 3.402

3.  Identifying a Potential Key Gene, TIMP1, Associated with Liver Metastases of Uveal Melanoma by Weight Gene Co-Expression Network Analysis.

Authors:  Ping Wang; Xuan Yang; Nan Zhou; Jinyuan Wang; Yang Li; Yueming Liu; Xiaolin Xu; Wenbin Wei
Journal:  Onco Targets Ther       Date:  2020-11-19       Impact factor: 4.147

4.  Epigenetic regulation of CXCR4 expression by the ocular microenvironment.

Authors:  Haochuan Li; Jerry Y Niederkorn; Leila Sadegh; Jessamee Mellon; Peter W Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-09       Impact factor: 4.799

5.  The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.

Authors:  Jianjun Bi; Peng Li; Chuanyin Li; Jie He; Ying Wang; He Zhang; Xianqun Fan; Renbing Jia; Shengfang Ge
Journal:  Tumour Biol       Date:  2015-10-22

6.  Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.

Authors:  Rosaria Gangemi; Valentina Mirisola; Gaia Barisione; Marina Fabbi; Antonella Brizzolara; Francesco Lanza; Carlo Mosci; Sandra Salvi; Marina Gualco; Mauro Truini; Giovanna Angelini; Simona Boccardo; Michele Cilli; Irma Airoldi; Paola Queirolo; Martine J Jager; Antonio Daga; Ulrich Pfeffer; Silvano Ferrini
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

Review 7.  Orchestrating epigenetic roles targeting ocular tumors.

Authors:  Xuyang Wen; Linna Lu; Zhang He; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2016-02-29       Impact factor: 4.147

8.  Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Authors:  Gülçin Gezgin; Mehmet Dogrusöz; T Huibertus van Essen; Wilhelmina G M Kroes; Gregorius P M Luyten; Pieter A van der Velden; Vonn Walter; Robert M Verdijk; Thorbald van Hall; Sjoerd H van der Burg; Martine J Jager
Journal:  Cancer Immunol Immunother       Date:  2017-04-08       Impact factor: 6.968

Review 9.  The biology of uveal melanoma.

Authors:  Adriana Amaro; Rosaria Gangemi; Francesca Piaggio; Giovanna Angelini; Gaia Barisione; Silvano Ferrini; Ulrich Pfeffer
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

10.  Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases.

Authors:  Shanshan Tan; Hua Yang; Shenghui Xue; Jingjuan Qiao; Mani Salarian; Khan Hekmatyar; Yuguang Meng; Rao Mukkavilli; Fan Pu; Oluwatosin Y Odubade; Wayne Harris; Yan Hai; Melinda L Yushak; Vanessa M Morales-Tirado; Pardeep Mittal; Phillip Z Sun; David Lawson; Hans E Grossniklaus; Jenny J Yang
Journal:  Sci Adv       Date:  2020-02-07       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.